Anadys Pharmaceuticals (ANDS) Higher After Positive Study Results
More News related to ANDS
- Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
- Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: ANDS, UMC, NTRS, SI, TTWO, APC
- JMP Starts Anadys Pharma (ANDS) at Market Outperform
- Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
- Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Neutral
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) is higher this morining after the company and LG Life Sciences, Ltd., presented data from an in vitro study showing that ANA380 (LB80380) retains potency against multiple mutant strains of hepatitis B virus (HBV) which are resistant to lamivudine, adefovir, entecavir or telbivudine.
The company said the study found that the in vitro antiviral potency of ANA380 against seven of nine mutants that were resistant to lamivudine, adefovir, entecavir or telbivudine was not significantly different from the antiviral potency against wild type HBV, indicated by a less than or equal to 2-fold difference in EC50, a measure of inhibition of virus replication. In addition, two HBV mutants that have been associated with clinical failure to entecavir or telbivudine, respectively, showed only small decreases (5 and 7 fold, respectively) in sensitivity to ANA380's antiviral effects in vitro. ANA380 was active against the HBV mutant resistant to telbivudine in prior clinical studies.
Related Categories
FDAMomentum Movers
Stocks Mentioned
-0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
